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Abstract
Background—The traditional HIV treatment cascade has been noted to have limitations. A 
proposed comprehensive HIV care cascade that uses cohort methodology offers additional 
information as it accounts for all patients. Using data from 4 countries, we compare patient 
outcomes using both approaches.
Methods—Data from 390,603 HIV-infected adults (>15 years) enrolled at 217 facilities in 
Kenya, Mozambique, Rwanda, and Tanzania from 2005 to 2011 were included. Outcomes of all 
patients at 3, 6, and 12 months after enrollment were categorized as optimal, suboptimal, or poor. 
Optimal outcomes included retention in care, antiretroviral therapy (ART) initiation, and 
documented transfer. Suboptimal outcomes included retention in care without ART initiation 
among eligible patients or those without eligibility data. Poor outcomes included loss to follow-up 
and death.
Results—The comprehensive HIV care cascade demonstrated that at 3, 6 and 12 months, 58%, 
51%, and 49% of patients had optimal outcomes; 22%, 12%, and 7% had suboptimal outcomes, 
and 20%, 37% and 44% had poor outcomes. Of all patients enrolled in care, 56% were retained in 
care at 12 months after enrollment. In comparison, the traditional HIV treatment cascade found 
89% of patients enrolled in HIV care were assessed for ART eligibility, of whom 48% were 
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determined to be ART-eligible with 70% initiating ART, and 78% of those initiated on ART 
retained at 12 months.
Conclusions—The comprehensive HIV care cascade follows outcomes of all patients, including 
pre-ART patients, who enroll in HIV care over time and uses quality of care parameters for 
categorizing outcomes. The comprehensive HIV care cascade provides complementary 
information to that of the traditional HIV treatment cascade and is a valuable tool for monitoring 
HIV program performance.
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INTRODUCTION
Scale-up of adult HIV care and treatment has been substantial with over 13 million adults 
receiving antiretroviral therapy (ART) by the end of 2014.1 The HIV treatment cascade is a 
tool that has been adapted by HIV programs to evaluate the quality of such activities by 
measuring the proportion of patients achieving essential steps in the HIV continuum of care 
that are necessary to maximize individual health and population prevention benefits of 
ART.2–4 The HIV treatment cascade’s ultimate end point is viral load suppression or 
retention after ART initiation in settings where viral load measurement is not available. 
However, the HIV treatment cascade does not follow outcomes of patients ineligible for 
ART, referred to as pre-ART patients. Thus, in many resource-limited settings where 
national and international guidelines currently do not recommend universal treatment, the 
traditional HIV treatment cascade does not provide a comprehensive assessment of all 
patient outcomes.
We propose an alternative approach, which we term the “comprehensive HIV care cascade,” 
that can be used to provide additional complementary information to that of the traditional 
HIV treatment cascade on HIV program performance. The comprehensive HIV care cascade 
uses cohort methodology to account for all patients who enroll in HIV programs over time 
irrespective of ART eligibility and uses quality-of-care categories (optimal, suboptimal, and 
poor) for grouping patient outcomes. This approach builds further on approaches aiming to 
capture outcomes for the subset of pre-ART patients.5–7 We posit that the comprehensive 
HIV care cascade could be an important tool that complements the traditional HIV treatment 
cascade to evaluate HIV program performance, at the health facility, across health facilities, 
or at regional or country levels.
The objectives of this analysis were (1) to use the comprehensive HIV care cascade to 
evaluate patient outcomes across ICAP-supported HIV programs using data from adults 
newly enrolling in HIV care in 4 sub-Saharan African countries and (2) to compare 
outcomes using the comprehensive HIV care cascade to those measured using the traditional 
HIV treatment cascade using these data.
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METHODS
Study Population
The study population includes data from HIV-infected adults aged 15 years or older who 
enrolled in HIV care at 217 HIV facilities in Kenya, Mozambique, Rwanda, and Tanzania 
from January 2005 to June 2011. Follow-up data were included through June 2012. 
Enrollment in HIV care was defined as completing at least 1 visit where clinical parameters 
(ie, height, weight, CD4+ cell count, or WHO stage) were recorded. Pre-ART patients were 
defined as individuals who were not on ART, including those with known ART ineligibility, 
unknown ART eligibility, or known ART eligibility but who were not initiated on treatment. 
The recommended package of pre-ART care included a provider assessment of a patient’s 
medical history and clinical examination and involved WHO staging, CD4+ count testing, 
screening for tuberculosis and sexually transmitted infections, and counseling regarding 
partner and family HIV testing and prevention interventions. ART patients were defined as 
those on ART. All facilities received technical support from ICAP at Columbia University 
through funding from the President’s Emergency Plan for AIDS Relief (PEPFAR).8 Health 
facilities included in this analysis participated in the Identifying Optimal Models Study, 
which used routinely collected patient- and facility-level data to measure patient and 
program outcomes.9 Patient information routinely collected during each clinic visit was 
documented by health care providers on national patient forms and subsequently entered by 
trained data clerks into a patient-level database. Data quality assessments were conducted 
quarterly to check for completeness and accuracy comparing paper records to data in 
electronic databases. Deidentified versions of electronic databases were compiled 
semiannually and shared with study investigators.
Traditional HIV Treatment Cascade Approach
In this analysis, the traditional HIV treatment cascade was adapted to use data routinely 
available for patients in sub-Saharan Africa and included the following steps: (1) number 
enrolled in HIV care, (2) number assessed for ART eligibility, (3) number determined ART 
eligible as per national guidelines, (4) number initiated on ART, and (5) number retained at 
12 months after ART initiation. Outcomes for pre-ART patients, time frames for 
achievement of each step (except the final step), and reasons for attrition between steps are 
commonly not included in this approach.5,10
Comprehensive HIV Care Cascade Approach
In the comprehensive HIV care cascade, outcomes for all patient enrolled in HIV care were 
assessed at 3, 6, and 12 months after enrollment and classified into the following mutually 
exclusive categories of optimal, suboptimal, and poor outcomes.
• “Optimal outcomes” included retained in pre-ART care with known ART 
ineligibility, initiated ART by the end of the given time point, retained on 
ART, or documented transfer.
• “Suboptimal outcomes” included retained in pre-ART care with known 
ART eligibility and retained in pre-ART care with undocumented or 
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indeterminate eligibility (eg, no available CD4+ count and/or WHO stage 
results to assess eligibility).
• “Poor outcomes” included loss to follow-up (LTF) or death, occurring 
either before or after ART initiation. Because ART initiation was assessed 
as the proportion initiating within 3 months, outcomes after ART initiation 
(death and LTF) were only assessed at the 6- and 12-month time points.
Assessment for ART eligibility was based on presence of documented CD4+ count and/or 
WHO clinical stage, and ART eligibility was determined based on prevailing national 
guidelines that largely reflected WHO recommendations at that point in time. For patients 
enrolling in care between 2005 and 2009, WHO 2006 guidelines were used.11 For patients, 
enrolling between 2010 and 2011, 2010 WHO guidelines were used (see Table, 
Supplemental Digital Content, http://links.lww.com/QAI/A710).12 Follow-up schedule for 
ART patients involved visits every 1–3 months and for pre-ART patients every 6–12 months 
as per country guidelines.
For the assessment at 3 months, patients were categorized into those initiating ART within 3 
months of enrollment and those who had not yet initiated ART at 3 months. Those not yet 
initiating ART at 3 months were further categorized into being retained in pre-ART care, 
documented transfer out, LTF, and recorded death before ART initiation. At 6 and 12 
months, additional categories were added to reflect outcomes after ART initiation, including 
retained on ART, LTF, and death after ART initiation.
Patients were categorized as retained in care if they were known to be alive and attending 
clinic with documented visits in the medical record. LTF was defined as no clinic visit for 6 
months for ART patients and 12 months for pre-ART patients with no subsequent visit or 
documented transfer or death. Patients who met the definition of LTF were assigned date of 
LTF 15 days after their last recorded visit. Death and transfers were determined from 
medical records. Patients with documented transfer were censored at their recorded date of 
transfer.
Statistical Analysis
For the traditional HIV treatment cascade, the proportion of patients achieving each step in 
the cascade was calculated as a conditional proportion (with the number achieving the 
previous step as the denominator). Retention on ART 12 months after ART initiation was 
estimated using Kaplan–Meier survival analytic techniques, with patients transferring out 
censored at their recorded transfer date. In the comprehensive HIV care cascade, at each 
time point in follow-up, patients were categorized into the mutually exclusive categories 
described above. Tests for differences in achievement of steps in the treatment and 
comprehensive cascade between countries were performed using χ2 tests.
Ethical Considerations
The Identifying Optimal Models Study was approved by each country’s ethics committee. 
The study was designated non-human subjects research by the Institutional Review Board at 
Columbia University Medical Center; the Center for Global Health at the US Centers for 
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Disease Control and Prevention determined the study to not involve engagement in human 
subject research.
RESULTS
Patient and Facility Characteristics
From January 2005 through June 2011, a total of 390,603 patients were newly enrolled in 
HIV care at 217 health facilities in Kenya, Mozambique, Rwanda, and Tanzania (Table 1). 
Most patients (52%) were enrolled in Mozambique, with 26% in Kenya, 14% in Tanzania, 
and 8% in Rwanda. Sixty-seven percent of patients were female, and the median age was 33 
years (Interquartile range, IQR, 27–71). Median CD4+ count at enrollment in HIV care was 
270 cells per microliter (IQR, 122–473), ranging from 218 cells per microliter (IQR, 89–
414) in Kenya to 395 cells per microliter (215–613) in Rwanda. At enrollment in care, 20% 
had a CD4+ count ≤200 cells per microliter and 34% of patients had a WHO Stage III/VI. 
Documentation of CD4+ count or WHO staging at enrollment was missing for 193,270 
(50%) and 98,873 (25%) of patients, respectively, with 58,474 (15%) of patients missing 
both enrollment CD4+ count and WHO staging. The proportion of patients missing both 
CD4+ count and a WHO Stage at enrollment ranged from 4.1% in Rwanda to 20.4% in 
Mozambique. The proportion missing both measures decreased over time across the entire 
cohort from 27% in 2005 to 10% in 2011. The median number of patients per facility was 
5037 in Mozambique as compared with 474 in Kenya, 437 in Rwanda, and 458 in Tanzania. 
Of all facilities, 56% were primary-level care facilities and 48% were located in rural areas.
Outcomes Based on the Traditional HIV Treatment Cascade
Of the 390,603 patients enrolled in HIV care, 345,839 (89%) were assessed for ART 
eligibility at any point during their follow-up period (Fig. 1). Of those assessed for ART 
eligibility, 167,523 (48%) were eligible for ART per national guidelines and 117,525 (70%) 
of the latter initiated treatment. Of patients who initiated ART, 91,211 (78%) were retained 
at 12 months after ART initiation. This approach does not report outcomes for 273,078 
patients (70% of all patients enrolled in care), which includes 44,764 patients (11% of all 
patients) who were not assessed for ART eligibility, 178,316 patients (46% of all patients) 
who were found to be ART ineligible, and 49,998 patients (13% of all patients) who were 
ART eligible but did not initiate treatment.
Outcomes Based on the Comprehensive HIV Care Cascade
Using the comprehensive HIV care cascade approach, outcomes for all 390,603 patients 
enrolled in care were determined at 3, 6, and 12 months after enrollment in care.
Optimal Outcomes
Of the 390,603 patients enrolled in HIV care, 58%, 51%, and 49% achieved optimal 
outcomes at 3, 6, and 12 months after enrollment in HIV care, respectively (Fig. 2A). 
Among the 227,134 patients (58% of all patients) who achieved optimal outcomes at 3 
months, 118,698 (30%) were ART-ineligible patients who were retained in pre-ART care, 
102,839 (26%) were patients initiating ART, and 5597 (1%) were patients who transferred 
care to another facility (Fig. 2B, Table S1, Supplemental Digital Content, http://
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links.lww.com/QAI/A710). Among the 190,122 (49%) patients who achieved optimal 
outcomes at 12 months, 64,833 (17%) were ART-ineligible patients who were retained in 
pre-ART care, 19,039 (5%) were patients initiating ART, 86,300 (22%) were patients 
retained on ART, and 19,950 (5%) were patients who transferred.
Suboptimal Outcomes
The proportion of all patients enrolled in HIV care with suboptimal outcomes decreased 
from 22% at 3 months to 7% at 12 months after enrollment in HIV care. At 3 months, 
50,352 patients with suboptimal outcomes (13% of the entire cohort) were ART eligible but 
had not yet initiated ART despite being retained in care and 33,911 (9%) were retained in 
care but had undocumented/indeterminate ART eligibility status (Fig. 2B, Table S1, 
Supplemental Digital Content, http://links.lww.com/QAI/A710). At 12 months, 18,376 (5%) 
patients were ART eligible but had not initiated ART and 10,149 (3%) were retained but had 
undocumented/indeterminate ART eligibility status.
Poor Outcomes
The proportion of patients with poor outcomes increased over time with 20% at 3 months, 
37% at 6 months, and 44% at 12 months after enrollment. Most patients categorized with 
poor outcomes were pre-ART patients who were LTF, and the proportion of these patients 
increased over time from 74,226 (19%) of all enrolled patients at 3 months to 136,118 (35%) 
at 12 months. The proportion of patients with documented death was similar among pre-
ART patients at 3, 6, and 12 months (1.3%, 1.6%, and 1.8%, respectively) and among ART 
patients at 6 and 12 months (1.1% and 1.6%, respectively) (Fig. 2B, see Table S1, 
Supplemental Digital Content, http://links.lww.com/QAI/A710).
Outcomes by Country Using Both Approaches
Examining outcomes by country using the HIV treatment cascade (Fig. 3), between 85% and 
98% of patients who enrolled in care were assessed for ART eligibility (χ2, P ≤ 0.0001 for 
difference between countries) and 67%–85% of ART-eligible patients initiated ART (P ≤ 
0.0001), with the largest proportion initiating ART in facilities in Rwanda. Retention among 
ART patients at 12 months after ART initiation ranged between 75% and 90% across 
countries, with the highest retention observed in Rwanda (P ≤ 0.0001).
Using the comprehensive HIV care cascade, more striking differences emerge by country. 
Optimal outcomes differed substantially at 12 months by country ranging from 41% to 83% 
(Kenya 52%, Mozambique 41%, Rwanda 83%, and Tanzania 51%, P ≤ 0.0001 for difference 
across countries) (Fig. 4). The smallest decrease in optimal outcomes over the 12-month 
period from enrollment was in Rwanda (4%) and the largest in Mozambique (12%). At 12 
months, Rwanda had a high proportion (83%) of patients with optimal outcomes, with 3% 
with suboptimal outcomes and 14% with poor outcomes—the majority of the latter involved 
pre-ART patients who were lost to follow-up.
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DISCUSSION
The comprehensive HIV care cascade is a valuable tool for monitoring HIV program 
performance as it provides additional and complementary information to that available in the 
traditional HIV treatment cascade approach. The key feature of the comprehensive HIV care 
cascade is inclusion of outcomes for all patients—both pre-ART and ART. In addition, the 
latter approach stratifies outcomes into 3 categories that reflect programmatic quality, that is, 
optimal, suboptimal, and poor outcomes, as well as measures these outcomes at specific time 
points from the date of enrollment in HIV care. Use of the traditional HIV treatment cascade 
approach to evaluate HIV program performance would not account for outcomes among 
273,078 of the 390,603 patients (70%) enrolled in care who did not initiate ART.
The proposed comprehensive HIV care cascade demonstrated that nearly half (49%) of all 
patients enrolled in HIV care had optimal outcomes, and 56% of all patients were retained in 
care at 12 months after enrollment. In comparison, the traditional HIV treatment cascade 
demonstrated that 78% of all patients who initiated ART were retained in care at 12 months 
after initiation, a proportion comparable with that noted in other studies.13,14 The latter 
outcome, which may appear at first glance more favorable, is because of its focus on a subset 
of patients enrolled in care—those who initiate ART. Several studies have shown that pre-
ART patients are at higher risk for LTF and death,15–18 and thus, it becomes critical to 
account for pre-ART patient outcomes to minimize poor outcomes for all patients enrolled in 
care.
An additional strength of the comprehensive HIV care cascade approach is that it accounts 
for patient outcomes over time using categories that reflect the quality of programs. In this 
analysis, optimal outcomes among pre-ART patients decreased over time, whereas poor 
outcomes (mainly LTFs) increased over time. Interestingly at 3 months follow-up, a similar 
proportion of pre-ART and ART patients (30% and 26%, respectively) had optimal 
outcomes, but by 12 months, 35% of all patients enrolled in care were pre-ART patients who 
were lost to follow-up—the largest subset of the entire cohort. This underscores the 
importance of designing retention interventions to be implemented early after enrollment in 
care for patients not eligible for ART at that point in time.
Patients with suboptimal outcomes offer a ready opportunity for interventions that could 
have favorable impact on program performance as these patients are still retained in care but 
may not have received appropriate medical care. For example, over time, the proportion of 
patients with undocumented ART eligibility assessment decreased, which could be further 
improved. HIV programs can prioritize initiating ART among eligible patients who have yet 
to start treatment. Delays in treatment initiation for ART-eligible patients have been shown 
to be associated with increase in mortality19 and a reduced likelihood of restoring CD4+ 
counts.20 Identifying and addressing the reasons for failure to initiate ART among eligible 
patients could potentially shift a substantial number of individuals from suboptimal to 
optimal outcome category. Appropriate interventions may include providing additional 
provider training on the importance of prompt ART initiation, counseling reluctant patients 
regarding the importance of ART for their health and well-being, and addressing their 
concerns about potential side effects associated with ART use.
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LTF was the main reason for poor outcomes in this cohort of patients, with greater LTF 
among pre-ART patients as compared with ART patients. However, it is important to note 
that patients categorized as LTF may represent a diverse group that includes those who have 
died or transferred to another health facility, but without documentation of either of these 
outcomes in their medical records, as well as those that have disengaged from care.21 Our 
findings demonstrate that HIV programs need to introduce interventions to reduce the high 
rates of LTF, particularly among pre-ART patients as indicated above.22,23 Retaining such 
individuals in care is critical so that they can be regularly monitored for their own health, for 
determination of ART eligibility, and to provide them with other interventions such as 
regular screening for tuberculosis, provision of co-trimoxazole and isoniazid prophylaxes, as 
appropriate, risk reduction counseling, and other supportive services.24,25
The comprehensive HIV care cascade also provides a more nuanced assessment of program 
performance across countries allowing for south-to-south learning and focused quality 
improvement activities. A stark difference was noted across countries in terms of proportion 
of patients with optimal outcomes, ranging from 41% to 83% based on findings from the 
analyses per the comprehensive HIV care cascade, largely because of differences in 
outcomes for pre-ART patients. The magnitude of difference would not have been 
appreciated if assessment was solely based on the use of the traditional HIV treatment 
cascade, which reported between 75% and 90% of patients initiated on ART retained at 12 
months after ART initiation across the 4 countries. One reason for the larger differences 
noted between countries in outcomes when using the comprehensive HIV care cascade is 
that a much smaller proportion (35%) of patients enrolled in HIV care in Rwanda were ART 
eligible as compared with Kenya (46%), Mozambique (52%), and Tanzania (53%). As 
studies have demonstrated superior retention for patients on ART as compared with pre-
ART, the focus on retention of patients on ART can mask substantial differences in overall 
program performance. Another potential explanation for the differences noted across 
countries may be patient age as fewer younger patients (15–24 years) were enrolled in care 
in Rwanda compared with Mozambique. Studies have reported lower retention rates in 
younger individuals.26 Finally, the larger number of patients followed by a health facility has 
been associated with inferior retention rates.27 In our study, the median number of patients 
per facility in Mozambique was significantly higher as compared with facilities in the other 
3 countries, which may have contributed to higher LTF in that country.28 It is possible that 
countries may have provided different pre-ART packages of care; some more attractive to 
patients. Regardless of the reason(s), the high proportion of patients with optimal outcomes 
observed from the data from Rwanda is consistent with findings from other studies.29–31
It is also important to note that the comprehensive HIV care cascade remains relevant as 
guidelines change and ART eligibility expands. For example, many countries are adopting 
the WHO 2013 guidelines, which recommend ART initiation for persons with CD4+ count 
<500 cells per microliter. In these settings, the proportion of pre-ART patients are likely to 
decrease over time; however, the recommended categories, that is, optimal, suboptimal, and 
poor outcomes, remain relevant and important in accounting for outcomes for all patients 
enrolled in care. Similarly, if treatment is expanded to include all HIV-infected patients, 
some patients will continue to be eligible for treatment but not initiated (a suboptimal 
outcome), or eligible for treatment but died before treatment start (a poor outcome). Also, 
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for countries where viral load monitoring becomes available, the comprehensive HIV care 
cascade can be adapted to include viral load suppression as the most distal outcome of 
interest.
The analysis has several strengths. The study includes a large cohort of adult patients 
enrolled in HIV care from sub-Saharan Africa from various types of health facilities and 
from diverse countries. The study used programmatic data allowing for generalizability of 
the findings. A limitation of the analysis is the issue of missing data, particularly of CD4+ 
count and WHO staging for ART eligibility determination, which is implicit in using 
routinely collected program data often using paper-based medical records. However, it is 
important to note that the comprehensive HIV care cascade includes outcomes for all 
patients including those with missing data.
CONCLUSIONS
In conclusion, the comprehensive HIV care cascade we describe offers additional and 
complementary information to the traditional HIV treatment cascade for assessing HIV 
program quality. The comprehensive approach accounts for all patients enrolled in HIV care 
irrespective of ART eligibility and/or treatment status, uses specific time frames from 
enrollment for measuring outcomes, and uses quality of care parameters for categorizing 
outcomes. Such an approach can be a better differentiator between programs with pre-ART 
patients regarding overall performance and can serve as a monitoring tool to identify gaps in 
service models and offer opportunities for specific interventions to improve outcomes. This 
approach has the potential to enhance quality and enable achievement of the full potential of 
the global HIV program scale-up.
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FIGURE 1. 
HIV treatment cascade (N = 390,603 adults at 217 facilities in Kenya, Mozambique, 
Rwanda, and Tanzania from January 2005 to June 2011).
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FIGURE 2. 
A, Comprehensive HIV care cascade with outcome categories, and (B) comprehensive HIV 
care cascade with subgroups within outcome categories (N = 390,603 adults at 217 facilities 
in Kenya, Mozambique, Rwanda, and Tanzania from January 2005 to June 2011).
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FIGURE 3. 
HIV treatment cascade by country program (N = 390,603 adults at 217 facilities in Kenya, 
Mozambique, Rwanda, and Tanzania from January 2005 to June 2011).
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FIGURE 4. 
Comprehensive HIV care cascade by county program (Kenya N = 101,938 patients at 85 
facilities, Mozambique N = 201,503 patients at 34 facilities, Rwanda N = 32,105 patients at 
41 facilities, and Tanzania N = 55,057 patients at 57 facilities).
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